Helicobacter pylori infection as an independent prognostic factor for locally advanced gastric cancer patients treated with adjuvant chemotherapy after curative resection

International Journal of Cancer

Volumn 130, Issue 4, 2012, Pages 948-958

  Kang, Seok Yun ^a   Han, Jae Ho ^a   Ahn, Mi Sun ^a   Lee, Hyun Woo ^a   Jeong, Seong Hyun ^a   Park, Joon Seong ^a   Cho, Yong Kwan ^a   Han, Sang Uk ^a   Kim, Young Bae ^a   Kim, Jang Hee ^a   Sheen, Seung Soo ^b   Lim, Ho Yeong ^c   Choi, Jin Hyuk ^a  

^a Ajou University School of Medicine   (South Korea)

^b Ajou University   (South Korea)

^c Sungkyunkwan University   (South Korea)

Author keywords

adjuvant chemotherapy; curative resection; gastric cancer; Helicobacter pylori; prognosis

Indexed keywords

DOXORUBICIN; FLUOROURACIL; KRESTIN; MITOMYCIN C; PICIBANIL;

ADULT; ADVANCED CANCER; AGE; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; GASTRECTOMY; HELICOBACTER INFECTION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PARTIAL GASTRECTOMY; PRIORITY JOURNAL; PROGNOSIS; STOMACH CANCER; STOMACH MUCOSA;

ADULT; AGED; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; GASTRECTOMY; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; STOMACH NEOPLASMS;

EID: 83955164290     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26081     Document Type: Article

References (41)

1. Fuchs CS, Mayer RJ,. Gastric carcinoma. N Engl J Med 1995; 333: 32-41.
2. Shin HR, Ahn YO, Bae JM, Shin MH, Lee DH, Lee CW, Ohrr HC, Ahn DH, Ferlay J, Parkin DM, Oh DK, Park JG,. Cancer incidence in Korea. Cancer Res Treat 2002; 34: 405-8.
3. Siewert JR, Bottcher K, Stein HJ, Roder JD,. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg 1998; 228: 449-61. (Pubitemid 30194389)
4. Kelsen DP,. Adjuvant and neoadjuvant therapy for gastric cancer. Semin Oncol 1996; 23: 379-89. (Pubitemid 26187738)
5. Macdonald JS,. Adjuvant therapy for gastric cancer. Semin Oncol 2003; 30: 19-25.
6. Cirera L, Balil A, Batiste-Alentorn E, Tusquets I, Cardona T, Arcusa A, Jolis L, Saigi E, Guasch I, Badia A, Boleda M,. Randomized clinical trial of adjuvant mitomycin plus tegafur in patients with resected stage III gastric cancer. J Clin Oncol 1999; 17: 3810-5.
7. Hermans J, Bonenkamp JJ, Boon MC, Bunt AM, Ohyama S, Sasako M, Van de Velde CJ,. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol 1993; 11: 1441-7. (Pubitemid 23228247)
8. Earle CC, Maroun JA,. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur J Cancer 1999; 35: 1059-64. (Pubitemid 29339187)
9. Mari E, Floriani I, Tinazzi A, Buda A, Belfiglio M, Valentini M, Cascinu S, Barni S, Labianca R, Torri V,. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente). Ann Oncol 2000; 11: 837-43.
10. Zhao SL, Fang JY,. The role of postoperative adjuvant chemotherapy following curative resection for gastric cancer: a meta-analysis. Cancer Invest 2008; 26: 317-25.
11. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007; 357: 1810-20. (Pubitemid 350044801)
12. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA,. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 725-30.
13. Marrelli D, De Stefano A, de Manzoni G, Morgagni P, Di Leo A, Roviello F,. Prediction of recurrence after radical surgery for gastric cancer: a scoring system obtained from a prospective multicenter study. Ann Surg 2005; 241: 247-55.
14. Kattan MW, Karpeh MS, Mazumdar M, Brennan MF,. Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma. J Clin Oncol 2003; 21: 3647-50. (Pubitemid 46594058)
15. Schistosomes liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7-14 June 1994. IARC Monogr Eval Carcinog Risks Hum 1994; 61: 1-241.
16. Ferreira AC, Isomoto H, Moriyama M, Fujioka T, Machado JC, Yamaoka Y,. Helicobacter and gastric malignancies. Helicobacter 2008; 13 (Suppl 1): 28-34.
17. Brenner H, Arndt V, Stegmaier C, Ziegler H, Rothenbacher D,. Is Helicobacter pylori infection a necessary condition for noncardia gastric cancer? Am J Epidemiol 2004; 159: 252-8. (Pubitemid 38141654)
18. Hocker M, Hohenberger P,. Helicobacter pylori virulence factorsâone part of a big picture. Lancet 2003; 362: 1231-3. (Pubitemid 37255353)
19. Lee WJ, Lin JT, Shun CT, Lee WC, Yu SC, Lee PH, Chang KJ, Wei TC, Chen KM,. Comparison between resectable gastric adenocarcinomas seropositive and seronegative for Helicobacter pylori. Br J Surg 1995; 82: 802-5.
20. Meimarakis G, Winter H, Assmann I, Kopp R, Lehn N, Kist M, Stolte M, Jauch KW, Hatz RA,. Helicobacter pylori as a prognostic indicator after curative resection of gastric carcinoma: a prospective study. Lancet Oncol 2006; 7: 211-22. (Pubitemid 43286451)
21. Marrelli D, Pedrazzani C, Berardi A, Corso G, Neri A, Garosi L, Vindigni C, Santucci A, Figura N, Roviello F,. Negative Helicobacter pylori status is associated with poor prognosis in patients with gastric cancer. Cancer 2009; 115: 2071-80.
22. Choi JH, Kim YB, Lim HY, Park JS, Kim HC, Cho YK, Han SW, Kim MW, Joo HJ,. 5-Fluorouracil, mitomycin-C, and polysaccharide-K adjuvant chemoimmunotherapy for locally advanced gastric cancer: the prognostic significance of frequent perineural invasion. Hepatogastroenterology 2007; 54: 290-7.
23. Choi J, Lim H, Nam DK, Kim HS, Cho DY, Yi JW, Kim HC, Cho YK, MW, Joo HJ, Lee KB, Kim KB,. Expression of thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection. Br J Cancer 2001; 84: 186-92. (Pubitemid 32113443)
24. Choi JH, Lim HY, Joo HJ, Kim HS, Yi JW, Kim HC, Cho YK, Kim MW, Lee KB,. Expression of multidrug resistance-associated protein1,P-glycoprotein, and thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection. Br J Cancer 2002; 86: 1578-85. (Pubitemid 34628111)
25. Greene FL, Compton CC, Fritz AG, Shah JP, Winchester DP,. American Joint Committee on Cancer: AJCC cancer staging manual, 6 edn. New York: Springer, 2002. 167-77.
26. The general rules for the gastric cancer study in surgery ad pathology,. Part II. Histological classification of gastric cancer. Jpn J Surg 1981; 11: 140-5.
27. Dixon MF, Genta RM, Yardley JH, Correa P,. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996; 20: 1161-81.
28. Kaplan EL, Meier P,. Non-parametric estimations from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
29. Cox D,. Regression model and life-tables. J R Stat Soc Ser 1972; 34: 187-220.
30. Kim JP, Lee JH, Kim SJ, Yu HJ, Yang HK,. Clinicopathologic characteristics and prognostic factors in 10 783 patients with gastric cancer. Gastric Cancer 1998; 1: 125-33.
31. Kasakura Y, Phan A, Ajani J,. Adjuvant therapy for resected gastric carcinoma. Surg Oncol Clin N Am 2002; 11: 431-44, xii-xiii. (Pubitemid 34951285)
32. Nakazato H, Koike A, Saji S, Ogawa N, Sakamoto J,. Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer. Lancet 1994; 343: 1122-6. (Pubitemid 24142032)
33. Chang HM, Jung KH, Kim TY, Kim WS, Yang HK, Lee KU, Choe KJ, Heo DS, Bang YJ, Kim NK,. A phase III randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil and mitomycin C versus 5-fluorouracil alone in curatively resected gastric cancer. Ann Oncol 2002; 13: 1779-85. (Pubitemid 35439458)
34. Ohno S, Inagawa H, Dhar DK, Fujii T, Ueda S, Tachibana M, Suzuki N, Inoue M, Soma G, Nagasue N,. The degree of macrophage infiltration into the cancer cell nest is a significant predictor of survival in gastric cancer patients. Anticancer Res 2003; 23: 5015-22. (Pubitemid 38182119)
35. Leung WK, Kim JJ, Kim JG, Graham DY, Sepulveda AR,. Microsatellite instability in gastric intestinal metaplasia in patients with and without gastric cancer. Am J Pathol 2000; 156: 537-43. (Pubitemid 30643809)
36. Wu MS, Lee CW, Sheu JC, Shun CT, Wang HP, Hong RL, Lee WJ, Lin JT,. Alterations of BAT-26 identify a subset of gastric cancer with distinct clinicopathologic features and better postoperative prognosis. Hepatogastroenterology 2002; 49: 285-9.
37. Hobsley M, Tovey FI, Holton J,. Helicobacter pylori and gastric cancer: neither friend nor foe. Gastroenterology 2007; 132: 2076. (Pubitemid 46677972)
38. Kato S, Matsukura N, Tsukada K, Matsuda N, Mizoshita T, Tsukamoto T, Tatematsu M, Sugisaki Y, Naito Z, Tajiri T,. Helicobacter pylori infection-negative gastric cancer in Japanese hospital patients: incidence and pathological characteristics. Cancer Sci 2007; 98: 790-4. (Pubitemid 46691814)
39. Genta RM, Graham DY,. Comparison of biopsy sites for the histopathologic diagnosis of Helicobacter pylori: a topographic study of H. pylori density and distribution. Gastrointest Endosc 1994; 40: 342-5. (Pubitemid 24163073)
40. Wu MS, Hung HW, Wang JT, Tseng CC, Shun CT, Wang HP, Lee WJ, Lin JT,. Helicobacter pylori-seronegative gastric carcinoma: a subset of gastric carcinoma with distinct clinicopathologic features. Hepatogastroenterology 1998; 45: 2432-6.
41. Van Cutsem E, Van de Velde C, Roth A, Lordick F, Kohne CH, Cascinu S, Aapro M,. Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group. Eur J Cancer 2008; 44: 182-94.